Godavari Biorefineries Limited has informed the Exchange regarding a press release dated July 07, 2025, titled "Godavari Biorefineries European Patent for anti -cancer molecule".
GODAVARIB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 1.0 pts less than its Fast Moving Consumer Goods peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Godavari Biorefineries (GBL) announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states. The molecule has shown effectiveness against cancer cells and cancer stem cells in preclinical studies, with potential applications in breast and prostate cancer treatment. It is currently undergoing Phase 1a clinical trials to test safety in humans with advanced solid tumors and in healthy volunteers. The work is being driven by the company's clinical-stage biotech arm, Sathgen Therapeutics. This move highlights GBL's diversification beyond its core ethanol, biofuels, and renewable chemicals business into advanced biotech research.
Positive sentiment for shareholders — the patent strengthens GBL's intellectual property position in a high-potential therapeutic area and signals diversification into biotech, though the molecule is still in early-stage trials, so commercial revenue remains years away.